B cell depletion in lupus and Sjögren's syndrome: An update

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 483-488

  Coca, Andreea ^a   Sanz, Ignacio ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

B cell depletion; Lupus nephritis; Rituximab; Sjogren's syndrome

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; PLACEBO; RITUXIMAB;

ANTIPHOSPHOLIPID SYNDROME; B LYMPHOCYTE; CELL FUNCTION; FOLLOW UP; HUMAN; INFECTION RISK; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIPHOSPHOLIPID SYNDROME; B-LYMPHOCYTES; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; LYMPHOCYTE DEPLETION; SJOGREN'S SYNDROME;

EID: 69549122987     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832efe55     Document Type: Review

References (39)

1. Merrill J, Neuwelt C, Wallace D, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. American College of Rheumatology National Meeting 2008; Abstract L12. This is the first randomized, double-blind trial employing B cell depletion in nonrenal lupus. Despite very encouraging preliminary data, this was a negative trial.
2. Manjarrez-Orduno N, Quach TD, Sanz I. B cells and immunological tolerance. J Invest Dermatol 2009; 129:278-288.
3. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patients. Arthritis Rheum 2009; 61:482-487. This study was a large retrospective analysis of B cell depletion as a rescue agent for patients with non-renal lupus refractory to conventional therapies. Rituximab was used in conjunction with cyclophosphamide, and this combination resulted in a decrease of BILAG score.
4. Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008; 35:826-833. A small study of refractory lupus, and autoantibody-mediated cytopenias that proved very responsive to B cell depletion therapy. (Pubitemid 351747123)
5. Melander C, Sallee M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4:579-587. A small case series where B cell depletion was effective for a combination of refractory, relapsing and new onset lupus nephritis.
6. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009; 24:2157-2160.
7. Erre GL, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17:50-55.
8. Ioannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis 2008; 67:425-426. (Pubitemid 351281283)
9. Jeffery RC, Narshi CB, Isenberg DA. Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients. Rheumatology (Oxford) 2008; 47:1379-1383.
10. Suzuki K, Nagasawa H, Kameda H, et al. Severe acute thrombotic exacerbation in two cases with antiphospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48:198-199.
11. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66:470-475. (Pubitemid 46580466)
12. Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 2009; 15:189-192.
13. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008; 67 (Suppl 3):iii64-iii65.
14. Calabrese LH, Molloy ES, Huang D, et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007; 56:2116-2128. (Pubitemid 47173558)
15. Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 2008; 126:282-290.
16. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66:1933-1948. (Pubitemid 44771932)
17. Anolik J, Sanz I. B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol 2004; 16:505-512. (Pubitemid 39128317)
18. Dass S, Rawstron AC, Vital EM, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58:2993-2999.
19. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti- CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67:1724-1731. This study illustrates the complexity of immune response that lupus patients mount to the therapeutic monoclonal antibodies, as well as the clinical impact of the resulting HACA.
20. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67:1011-1016. Variability of BlyS levels during B cell depletion suggests that it could be considered as a potential biomarker and predictor of disease activity. (Pubitemid 351956665)
21. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119:1066-1073.
22. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56:3044-3056. (Pubitemid 47502752)
23. Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008; 93:401-406. A retrospective analysis of B cell depletion in renal and non-renal lupus that demonstrates significant improvement in BILAG score in the pediatric population. (Pubitemid 352025791)
24. Kumar S, Benseler SM, Kirby-Allen M, et al. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009; 123:e159-e163.
25. Looney RJ. Will targeting B cells be the answer for Sjogren's syndrome? Arthritis Rheum 2007; 56:1371-1377.
26. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008; 67:1541-1544. This is the first positive double blind trial of B cell depletion in Sjogren's syndrome.
27. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284-285.
28. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006; 70:1403-1412.
29. Balow JE, Austin HA 3rd. Treatment of proliferative lupus nephritis. Am J Kidney Dis 2004; 43:383-385.
30. Isenberg D, Gordon C, Merrill J, et al. New therapies in systemic lupus erythematosus - trials, troubles and tribulations.. . . working towards a solution. Lupus 2008; 17:967-970.
31. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:476-480. (Pubitemid 44200330)
32. Wallace DJ. New therapies in systemic lupus erythematosus - trials, troubles and tribulations - working towards a solution: part 2: the politically incorrect version. Lupus 2009; 18:101-103.
33. Bertsias GK, Ioannidis JP, Boletis J, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. Ann Rheum Dis 2009; 68:477-483.
34. Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun 2009; 32:223-230.
35. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17:191-197. (Pubitemid 46929903)
36. Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009; 8:343-348.
37. Lu TY, Jonsdottir T, van Vollenhoven RF, et al. Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases. Ann Rheum Dis 2008; 67:1493-1494.
38. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793-2806. (Pubitemid 44497758)
39. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.